EUVIMEDOpdag EUVIMED
Crossref

Mesenchymal Stem Cell-Based Biomimetic Liposome for Targeted Treatment of Rheumatoid Arthritis

Lan Ma, Honghui Wu, Jian Cao, Nan Zhang iD, Yaosheng Li, Juanjuan Zheng, Xinchi Jiang, Jianqing Gao iD

ACS Applied Materials & Interfaces · 2024

DOI: 10.1021/acsami.4c09080 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2024. Written by Lan Ma and 7 co-authors. Institution: State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Major MEDLINE topics: Mesenchymal Stem Cells, Liposomes, Arthritis, Rheumatoid, Dexamethasone. Cited 13 times so far (Crossref); 42 references. Funded by: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Rheumatoid arthritis (RA) is a systemic autoimmune disorder that severely compromises joint health. The primary therapeutic strategy for advanced RA aims to inhibit joint inflammation. However, the nonspecific distribution of pharmacological agents has limited therapeutic efficacy and heightens the risks associated with RA treatment. To address this issue, we developed mesenchymal stem cell (MSC)-based biomimetic liposomes, termed MSCsome, which were composed of a fusion between MSC membranes and liposomes. MSC some with relatively simple preparation method effectively enhanced the targeting efficiency of drug to diseased joints. Interaction between lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 enhanced the affinity of the MSCsome for polarized macrophages, thereby improving its targeting capability to affected joints. The effective targeted delivery facilitated drug accumulation in joints, resulting in the significant inhibition of the inflammation, as well as protection and repair of the cartilage. In conclusion, this study introduced MSCsome as a promising approach for the effective treatment of advanced RA, providing a novel perspective on targeted drug delivery therapy for inflammatory diseases.

Subjects

MeSH terms (MEDLINE)

Mesenchymal Stem CellsLiposomesArthritis, RheumatoidDexamethasoneDrug Delivery SystemsHumansAnimalsMiceHuman Umbilical Vein Endothelial CellsMice, Inbred BALB CMice, Inbred DBAMaleBiomimeticsCartilage

Author keywords

LFA-1/ICAM-1biomimetic nanocarriermacrophage targetingmesenchymal stem cell membranerheumatoid arthritis

Substances

LiposomesDexamethasone

Authors and institutions

  • State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • College of Pharmacy, Inner Mongolia Medical University, Chilechuan Dairy Economic Development Zone, Hohhot, Inner Mongolia Autonomous Region 010110, China.
  • Jinhua Institute of Zhejiang University, Jinhua 321002, China.
  • Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

ORCID profiles: Nan Zhang, Jianqing Gao

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Cite

APA

Ma, L., Wu, H., Cao, J., Zhang, N., Li, Y., Zheng, J., Jiang, X., & Gao, J. (2024). Mesenchymal Stem Cell-Based Biomimetic Liposome for Targeted Treatment of Rheumatoid Arthritis. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c09080

Vancouver

Ma L, Wu H, Cao J, Zhang N, Li Y, Zheng J, et al. Mesenchymal Stem Cell-Based Biomimetic Liposome for Targeted Treatment of Rheumatoid Arthritis. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c09080

BibTeX
@article{Ma2024,
  author = {Ma, Lan and Wu, Honghui and Cao, Jian and Zhang, Nan and Li, Yaosheng and Zheng, Juanjuan and Jiang, Xinchi and Gao, Jianqing},
  title = {Mesenchymal Stem Cell-Based Biomimetic Liposome for Targeted Treatment of Rheumatoid Arthritis},
  journal = {ACS Applied Materials & Interfaces},
  year = {2024},
  doi = {10.1021/acsami.4c09080}
}
Start for free →